Viewpoint
Abstract
Broadly activating innate immunity, which has been achieved via unrelated vaccines or Type-I INF-like factors, may effectively treat or prevent COVID-19 and future coronavirus diseases.
Authors
Leonard Angka, Marisa Market, Michele Ardolino, Rebecca C. Auer
Abstract
Authors
Lucy Y. Ghoda, Steven T. Rosen, Larry W. Kwak
Abstract
Authors
David T. Ting, Julius J.S. Knowles
Abstract
Authors
Norman E. Sharpless
Abstract
In COVID-19, complement activation may contribute to hemostatic activation leading to pathological features such as microvascular injury and coagulopathy.
Authors
Wen-Chao Song, Garret A. FitzGerald
Abstract
Authors
Mark Donowitz, Jerrold R. Turner, Alan S. Verkman, Nicholas Constantine Zachos
Abstract
Authors
Laura E. Crotty Alexander, Amy L. Bellinghausen, Michelle N. Eakin
Abstract
This Viewpoint calls on investigators that are developing and testing therapeutic and prophylactic approaches for COVID-19 to design studies that are inclusive of male-female differences.
Authors
Evelyne Bischof, Jeannette Wolfe, Sabra L. Klein
Abstract
Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.
Authors
Maximilian F. Konig, Michael A. Powell, Verena Staedtke, Ren-Yuan Bai, David L. Thomas, Nicole M. Fischer, Sakibul Huq, Adham M. Khalafallah, Allison Koenecke, Ruoxuan Xiong, Brett Mensh, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Joshua T. Vogelstein, Susan Athey, Shibin Zhou, Chetan Bettegowda
No posts were found with this tag.
Copyright © 2020 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)